1. | BUYtheWeak | |
2. | nlanas2sk051p | |
3. | MamisTrist | |
4. | johnhoar | |
5. | orangepa53 |
1. | BUYtheWeak | |
2. | nlanas2sk051p | |
3. | MamisTrist | |
4. | johnhoar | |
5. | orangepa53 |
1. | johnhoar 03/10/2018 Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate |
2. | johnhoar 02/08/2018 BMO Capital reiterates |
3. | BUYtheWeak 09/12/2017 @MamisTrist Yup, looking like it if you haven't already |
4. | johnhoar 01/30/2018 Great news - Company granted orphan drug designation by the FDA for its compound for the treatment of follicular lymphoma |
5. | MamisTrist 09/17/2018 Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis |
6. | BUYtheWeak 04/30/2018 FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma |
7. | nlanas2sk051p 05/21/2018 New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma |
8. | BUYtheWeak 04/03/2018 Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency has accepted for review th… |
9. | MamisTrist 09/12/2017 Time to buy? |
10. | johnhoar 04/03/2018 EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma |